Live tape
Top 8, mentions 7d14,338NVDA4,854 mentions▲ +0.04GOOGL2,061 mentions▲ +0.04SPY1,736 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,106 mentions▲ +0.05TSLA954 mentions▲ +0.04SNDK861 mentions▲ +0.05

Equity · Healthcare

SNDX

NASDAQ

Syndax Pharmaceuticals (SNDX)

9.53 USD +2.14% vs prior close Nov 6, 2026
Syndax Pharmaceuticals, Inc. price graph
54 sessions
25 5 12 Aug 6 Nov

The line runs 20 USD on 12 August through 9.53 USD on 6 November, on a scale from 5 to 25. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView
Market cap
850.6M USD
Revenue, year to Dec 2025
172.4M USD
EPS, diluted, year to Dec 2025
−3.29 USD
52-week range
9.33 USD – 25.15 USD
Avg volume
220.4K

as of Nov 6, 2026

Have Syndax Pharmaceuticals (SNDX) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Syndax Pharmaceuticals insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Dec 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 29 Oct 2026

0buys
1sells
$114Knet sold
1other filings
Have Syndax Pharmaceuticals (SNDX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
29 Oct 2026Podlesak DennisDirectorSell8,000114K USD
1 other filing in the window: a grant, exercise, tax withholding or transfer, not a trade
Have Syndax Pharmaceuticals (SNDX) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
29 Oct 2026Podlesak DennisDirectorOption exercise8,00094K USD

Which funds hold Syndax Pharmaceuticals (SNDX)?

7 of the 45 institutional funds we track reported a Syndax Pharmaceuticals position for the quarter ended 30 Jun 2026 — a combined 142.5M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Syndax Pharmaceuticals (SNDX)?
FundPositionSharesValueShares q/q
Millennium ManagementAdded2,053,96044.9M USD+929.4%
Two Sigma InvestmentsHeld (±25%)1,578,12534.5M USD−0.1%
D. E. Shaw & Co.Held (±25%)1,239,95427.1M USD−22.6%
AQR Capital ManagementHeld (±25%)853,30418.7M USD−13.0%
Renaissance TechnologiesTrimmed321,6007.0M USD−35.4%
Citadel AdvisorsTrimmed258,2785.6M USD−59.1%
Man GroupHeld (±25%)213,7034.7M USD+17.4%
Marshall WaceExited
Point72 Asset ManagementExited
Tudor Investment CorpExited

What has been filed or recorded for Syndax Pharmaceuticals (SNDX)?

The filings we hold for Syndax Pharmaceuticals, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 30 Sep 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Syndax Pharmaceuticals (SNDX)?
And
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.55 USDRevenue $83M
30 Sep 2026FinancialsTotal assets692.7M USDat period end
30 Sep 2026FinancialsTotal equity−17.2M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.55 USDRevenue $73M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.48 USDRevenue $65M
31 Dec 2025Annual reportFY 2025 reportedEPS −3.29 USDRevenue $172M
31 Dec 2025FinancialsRevenue172.4M USDfiscal year
31 Dec 2025FinancialsNet income−285.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−3.29 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.70 USDRevenue $46M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.83 USDRevenue $38M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.98 USDRevenue $20M
31 Dec 2024Annual reportFY 2024 reportedEPS −3.72 USDRevenue $24M

What do people ask about Syndax Pharmaceuticals (SNDX)?

From live data
What did Syndax Pharmaceuticals shares close at?9.53

Syndax Pharmaceuticals closed at 9.53 USD on 6 Nov 2026, up 2.14% on the close before. That is the end-of-day price from Finazon, not a live quote.

What is Syndax Pharmaceuticals’ market cap?850.6M

Syndax Pharmaceuticals is worth 850.6M USD by market value as of 6 Nov 2026, which is the share price times the shares on issue from its SEC filings.

What is Syndax Pharmaceuticals’ revenue?172.4M

Syndax Pharmaceuticals reported revenue of 172.4M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

Have Syndax Pharmaceuticals insiders bought or sold shares recently?1 sale

In the 90 days to 10 Nov 2026, Syndax Pharmaceuticals insiders reported 1 open-market sale and no purchases (SEC Form 4); the filings we hold, back to 1 Dec 2025, show no open-market purchase. A further 1 filing was a grant, award, gift or exercise rather than an open-market trade. See Insiders

Which funds own Syndax Pharmaceuticals?7 of 45

7 of the 45 funds we track reported a Syndax Pharmaceuticals position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Millennium Management, Two Sigma Investments and D. E. Shaw & Co. See Funds

When did Syndax Pharmaceuticals last report earnings?−0.55

Syndax Pharmaceuticals last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.55 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  6. SEC EDGARreported earnings figures and scheduled report dates
  7. SEC EDGARValuation computed from SEC EDGAR filings